Biotech Values

[masterlongevity]

i can name about 500 KOL neurologists across the globe. am neuroscientist myself and know many many others.

Its doesn't matter what other therapies ahve shown. The FDA is not going to approve this unless there is a primary endpoint that is clinically meaningul in phase 3 and it hits.

all but one of the clinical endpoints in this study were negative, and we dont know the statistical method used for that one. I will wait on see the real data on Hippocampal atrophy. call me skeptical there as well.

By the way, in the AD world, there have been quite a few compounds that hit on one posthoc analysis of a subset of clinical endpoint and on a biomarker. most of those have died.